TD Ameritrade Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

TD Ameritrade Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-640	Closed	-$91K	–	666
2021 Q3	$91K	Buy	640 +59	+10%	+$8.91K	﹤0.01%	265
2021 Q2	$103K	Sell	581 -14	-2%	-$2.42K	﹤0.01%	278
2021 Q1	$98K	Hold	595	–	–	﹤0.01%	272
2020 Q4	$98K	Sell	595 -45	-7%	-$6.7K	﹤0.01%	272
2020 Q3	$91K	Buy	640 +167	+35%	+$20.7K	﹤0.01%	265
2020 Q2	$52K	Buy	473 +156	+49%	+$17.3K	﹤0.01%	306
2020 Q1	$32K	Buy	317 +48	+18%	+$6.21K	﹤0.01%	329
2019 Q4	$40K	Buy	269 +202	+301%	+$27.5K	﹤0.01%	332
2019 Q3	$9K	Buy	67 +3	+5%	+$402	﹤0.01%	448
2019 Q2	$9K	Sell	64 -258	-80%	-$34.7K	﹤0.01%	410
2019 Q1	$46K	Buy	+322	New	+$42K	﹤0.01%	250

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TD Ameritrade Investment Management's JAZZ Position: Q4 2021 in Review

TD Ameritrade Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 640 shares — an estimated $91K sold.

TD Ameritrade Investment Management first reported a position in JAZZ in Q1 2019 and held it in 11 quarters. The position peaked at $103K in Q2 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

TD Ameritrade Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
TD Ameritrade Investment Management sold 640 Jazz Pharmaceuticals shares in Q4 2021, an estimated $91K.
TD Ameritrade Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 11 quarters.
TD Ameritrade Investment Management's Jazz Pharmaceuticals position peaked at $103K in Q2 2021.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on TD Ameritrade Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.